Cardiovascular risks and bleeding with non-vitamin K antagonist oral anticoagulant versus warfarin in patients with type 2 diabetes: a tapered matching cohort study.
Dahai YuZhanzheng ZhaoDavid SimmonsPublished in: Cardiovascular diabetology (2020)
Incident NOAC use among T2DM is associated with increased risk of bleeding hospitalisation and CVD re-hospitalisation compared with incident warfarin use. For T2DM, caution is required in prescribing NOACs as first anticoagulant treatment. Further large-scale replication studies in external datasets are warranted.
Keyphrases
- atrial fibrillation
- oral anticoagulants
- direct oral anticoagulants
- venous thromboembolism
- cardiovascular disease
- primary care
- emergency department
- type diabetes
- glycemic control
- metabolic syndrome
- case control
- risk assessment
- combination therapy
- skeletal muscle
- replacement therapy
- insulin resistance
- smoking cessation